Menu
Search
|

Menu

Close
X

Geron Corp GERN.OQ (NASDAQ Stock Exchange Global Select Market)

2.38 USD
+0.00 (+0.00%)
As of Feb 16
chart
Previous Close 2.38
Open 2.37
Volume 423,306
3m Avg Volume 376,052
Today’s High 2.53
Today’s Low 2.36
52 Week High 3.14
52 Week Low 1.75
Shares Outstanding (mil) 159.21
Market Capitalization (mil) 366.19
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.67 Mean rating from 3 analysts

KEY STATS

Revenue (mm, USD)
FY17
1
FY16
6
FY15
36
EPS (USD)
FY17
-0.085
FY16
-0.186
FY15
-0.005
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.90
Price to Sales (TTM)
vs sector
61.93
5.77
Price to Book (MRQ)
vs sector
3.24
5.41
Price to Cash Flow (TTM)
vs sector
--
23.42
Total Debt to Equity (MRQ)
vs sector
0.00
16.52
LT Debt to Equity (MRQ)
vs sector
0.00
12.22
Return on Investment (TTM)
vs sector
-21.08
14.43
Return on Equity (TTM)
vs sector
-21.08
16.13

EXECUTIVE LEADERSHIP

Hoyoung Huh
Independent Chairman of the Board, Since 2011
Salary: --
Bonus: --
John Scarlett
President, Chief Executive Officer, Director, Since 2012
Salary: $586,500.00
Bonus: $70,380.00
Olivia Bloom
Chief Financial Officer, Executive Vice President - Finance, Treasurer, Since 2014
Salary: $365,000.00
Bonus: $16,425.00
Stephen Rosenfield
Executive Vice President, General Counsel and Corporate Secretary, Since 2012
Salary: $312,000.00
Bonus: $14,040.00
Andrew Grethlein
Executive Vice President - Development and Technical Operations, Since 2014
Salary: $379,000.00
Bonus: $17,055.00

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

149 Commonwealth Dr Ste 2070
MENLO PARK   CA   94025-1133

Phone: +1650.4737700

Geron Corporation (Geron) is a biopharmaceutical company, which supports the clinical stage development of a telomerase inhibitor, Imetelstat, in hematologic myeloid malignancies by Janssen Biotech, Inc. (Janssen). The Company is engaged in the development of therapeutic products for oncology. Using its nucleic acid chemistry, Geron designed Imetelstat to be an oligonucleotide that binds with high affinity to the ribonucleic acid (RNA) template of telomerase, thereby directly inhibiting telomerase activity. Janssen is engaged in the development of Imetelstat with two clinical trials, such as a Phase II trial in myelofibrosis (MF), referred to as IMbark, and a Phase II/III trial in myelodysplastic syndromes (MDS) referred to as IMerge. Imetelstat is a lipid conjugated 13-mer oligonucleotide that is designed to be complementary to and bind with high affinity to the RNA template of telomerase, thereby directly inhibiting telomerase activity.

SPONSORED STORIES